Semaglutide & Liraglutide continue to be effective
Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.
Latest
Lizzo's as a lens on GLP1 public opinion
We view the the reflection of public opinion on GLP1s and drugs like Ozempic, Mounjaro, and Zepbound through an unusual lens: Lizzo.
Eli Lilly brands GLP1s as "anti-hedonics"
Eli Lilly leans into the use of GLP1s for reducing addictive behavior, labeling them "anti-hedonics"
How much are people paying for GLP1s? (2024/11)
We take another look at reports of what people are paying for GLP1s with/without insurance and everywhere in between.
A list of FDA approved GLP1s
A list of FDA approved GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc), for easy reference.
Anxiety and suicidal thoughts after stopping GLP1s?
Reports of anxiety and suicidal reports have been reported for people after *stopping* use of GLP1s. We dig in, and weight the FDA's comments.
Biden-Harris administration keen on GLP1s
The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
Weight loss "stalling" on GLP1s?
What happens when weight loss stalls on GLP1s? We check around the GLP1 community to see what people have figured out.
The UK's bet on GLP1
A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.
Research on GLP1 Signaling in the brain
How does GLP1 signal the brain? We take a look at related research to try and learn more.
GLP1s and Osteoarthritis
Newly published research explores the link between Osteoarthritis and GLP1s -- positive results that are somewhat predictable.
Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
Semaglutide's link to blinding disease (NAION)
We explore the link between blinding disease/vision loss and Semaglutide, as reported by medical research.
Patent expirations for GLP1 Receptor Agonists
How long will we have to wait for generic versions of GLP1 drugs? We take a look at patent expiry dates for the most popular brands & GLP1 formulations.
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
category:news
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
category:news
GLP1s and Sleep Apnea
GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea
Habener, Mosjov and Knudsen win the Lasker award
The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.
category:news
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
categeory:watercooler
Novo's CEO will testify, but change is unlikely
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.
categeory:watercooler
Reminder: Ozempic face isn't real
Ozempic face isn't real -- fast weight loss causes changes to the skin, and your face is a prime area that will change.
drug:am-133
Amgen's GLP1: MariTide (formerly AMG-133)
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.
company:eli-lilly
Eli Lilly's other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
GLP1 reverses diabetes in human cells (in mice)
Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.
category:side-effects
Thyroid issues with GLP1?
Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?
includes:study
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
category:news
23andMe gets into GLP1
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
includes:review
Systematic reviews of GLP1 worth reading
Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.
drug:amycretin
Novo's new GLP1: Amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
GLP1's effect on ADHD
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.
categeory:watercooler
Life before GLP1s: Topiramate
Wondering what the world was doing before GLP1s? We discuss Topiramate, a popular appetite suppressant.